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ABSTRACT
Most breast cancers express androgen receptors (AR). This prospective imaging sub-study
explored imaging AR with 18F-fluoro-5α-dihydrotestosterone (FDHT)-PET in patients with
metastatic breast cancer (MBC) receiving selective AR modulation (SARM) therapy (GTx-024).
Methods: 11 post-menopausal women with estrogen receptor positive MBC underwent FDHTPET/CT at baseline, 6, and 12 weeks after starting SARM therapy. Abnormal tumor FDHT
uptake was quantified using maximum SUV (SUVmax). AR status was determined from tumor
biopsy specimens. FDHT-SUVmax percent change between scans was calculated. Best overall
response was categorized as clinical benefit (CB: non-progressive disease [PD]), or PD using
RECIST 1.1).
Results: Median baseline FDHT-SUVmax was 4.1 (range 1.4-5.9) for AR+ tumors versus 2.3
(range 1.5-3.2) for AR- tumors (p=0.22). Quantitative AR expression and baseline FDHT uptake
were weakly correlated (Pearson rho=0.39, p=0.30). Seven participants with CB at 12 weeks
tended to have larger declines in FDHT uptake compared to those with PD at both 6 (median
decline, range: -26.8%, -42.9 to -14.1% vs. -3.7%, -31% to +29%, respectively, p=0.11) and 12
weeks (median decline, range: -35.7%, -69.5 to -7.7% vs. -20.1%, -26.6% to +56.5%,
respectively, p=0.17) after starting GTx-024.
Conclusion: This hypothesis-generating data suggests that FDHT-PET/CT is worth further study
as an imaging biomarker for evaluating response of MBC to SARM therapy and reiterates the
feasibility of including molecular imaging in multidisciplinary therapeutic trials.

Key Words: FDHT, androgen receptor, AR, PET, positron emission tomography, breast cancer
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INTRODUCTION
The androgen receptor (AR), the most abundantly expressed steroid hormone receptor in
breast cancer, is co-expressed in 75-95% of estrogen receptor positive (ER+) and 10-35% of
triple negative (ER negative [-]/PR-/HER2-) tumors (1). Steroidal androgens, notably
dihydrotestosterone (DHT) and fluoxymesterone, were widely used in the 1970s to treat
metastatic breast cancer (MBC), but virilizing side effects, concern for aromatization to estrogen,
and the survival benefit found with tamoxifen led to their disfavor (2,3). Recently, AR has reemerged as a therapeutic target in MBC due to elucidation of the complex relationship between
the AR-axis and breast cancer growth and the development of selective androgen receptor
modulators (SARMs).
In ER+ breast cancer, AR primarily inhibits tumor proliferation (4,5). GTx-024 is a novel oral
non-steroidal SARM which specifically binds AR promoting agonist activity. GTx-024 does not
bind other steroidal receptors and cannot be aromatized to estrogen (6). GTx-024 slowed tumor
growth in preclinical models of ER+ breast cancer and was well-tolerated without virilizing
effects (6).
Derived from DHT, 18F-fluoro-5α-dihydrotestosterone (FDHT) was developed for imaging
AR with positron emission tomography (PET) (7,8). In prostate cancer, FDHT-PET can
quantitate relative levels of AR and be used as a pharmacodynamic imaging biomarker after antiandrogen therapy to provide information about drug-targeting, dose-optimization, and response
(9).
Overmoyer et al. conducted a prospective phase II clinical trial of GTx-024 in
postmenopausal women with ER+ MBC (10). As part of this phase II clinical trial, we performed
a prospective imaging sub-study designed to (1) determine the feasibility of FDHT-PET/CT to
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non-invasively image AR expression in ER+ MBC, and (2) explore the potential of FDHT-PET
as an imaging biomarker for evaluating response to SARM therapy.

MATERIALS AND METHODS
Study Design and Participants
This single-site prospective imaging sub-study was performed as part of a larger open-label,
multicenter, international, randomized, parallel design phase II trial exploring the clinical benefit
(CB) of GTx-024 (G200802, GTx, Inc, NCT02463032). Participants were randomized 1:1 to
receive 9 or 18 mg of GTx-024 orally per day. The trial followed Declaration of Helsinki
principles and Good Clinical Practice and was approved by our institutional review board. All
participants gave informed written consent.
Major eligibility criteria for both the parent therapeutic trial and the imaging sub-study were
postmenopausal women with ER+/HER2-, metastatic or locally recurrent advanced breast
cancer, radiological or clinical disease recurrence or progression within 30 days of
randomization onto the therapeutic trial, ≥ 1 prior hormonal treatment but ≤ 1 course of
chemotherapy for metastatic disease, available biopsy or archival tumor tissue , bone-only nonmeasurable or measurable disease by RECIST 1.1, adequate organ function, and Eastern
Cooperative Oncology Group performance status ≤ 1. Participants only received the study drug
(GTx-024) and no other hormonal treatment for breast cancer while on study.

FDHT-PET/CT Scan Acquisition and Image Interpretation
FDHT-PET/CT scans were performed at baseline, 6, and 12 weeks after starting GTx-024
(Figure 1). Brigham and Women’s Nuclear Medicine/Biomedical Imaging Research Core
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manufactured FDHT under IND 122,852 per previously published methods (11,12). The final
formulated FDHT passed all quality control tests required for clinical use and had radiochemical
purity >99% and specific activity>18.5 GBq/µmol for all batches.
No specific preparation was given for FDHT-PET/CT scans. Forty-five minutes after
intravenous FDHT administration (333 MBq; 9 mCi), PET scans were obtained in 3D mode
from skull vertex to mid-thighs using 3-5 min per bed position (Discovery ST or Discovery MI,
GE Healthcare). Images were reconstructed using iterative methods. Non-contrast low-dose CT
imaging (3.75-5 mm axial slice thickness) was performed over the same range without breathhold for anatomic correlation and attenuation correction. For 7 participants, all FDHT-PET/CT
scans were obtained on the same scanner. A scanner upgrade during the study period
necessitated performance of the 12-week scan for 4 participants on a different scanner.
Lesions on FDHT-PET/CT scan were determined by comparison to the diagnostic contrastenhanced chest, abdomen and pelvis CT scans used to determine eligibility for the parent
therapeutic trial. FDHT uptake was quantitated in measurable lesions >1 cm in one dimension
and in non-measurable bone lesions which were allowed on this trial. The following semiquantitative parameters of FDHT uptake in tumor were recorded at all imaging time points:
maximum standardized uptake value corrected for body weight (SUVmax) and corrected for lean
body mass (SULmax), SUVpeak (average SUV in 1-cm3 volume of interest at the tumor’s
hottest part), SULpeak, and SUVmean in a 70% iso-contour around SUVmax.

Response Assessments
Objective disease response was determined according to RECIST 1.1 in the parent therapeutic
trial using contrast-enhanced CT/MRI and bone scans per standard institutional protocols at
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baseline, week 12 after starting GTx-024, and every 12 weeks until progressive disease (PD) or
study drug discontinuation. CB was defined as complete or partial response or stable disease per
RECIST 1.1. No CB was defined as PD. Best overall response (BOR) was defined as best tumor
response achieved from treatment start until treatment end. Because FDG-PET/CT is not
considered standard of care for assessing treatment response of MBC per National
Comprehensive Cancer Network guidelines (13) and it was not available at all international sites
participating in the parent therapeutic trial, FDG-PET/CT was not included for baseline and
disease response assessments.

Pathology and Laboratory Correlates
Tumor tissue from biopsy or archival tissue was reviewed for AR status using standard
immunohistochemical techniques with a monoclonal antibody specific for human AR by a
central laboratory (QualTek, Goleta, CA). AR was reported qualitatively as positive (i.e., >1%
percentage of positive nuclei) or negative and quantitatively as percentage of positive nuclei. The
local laboratory evaluated serum for estradiol, testosterone, and sex-hormone binding globulin
(SHBG) levels at baseline and serum prostate specific antigen (PSA) levels at baseline, 6-weeks,
and 12-weeks after therapy.

Statistical Analyses
The parent therapeutic trial’s primary endpoint was CB at 24 weeks after starting GTx-024.
Therefore, participants in the imaging sub-study were followed until the 24-week assessment.
The lesion with the highest FDHT uptake at baseline was correlated with AR status. Percent
change in FDHT uptake using the single-hottest lesion and sum of all measured lesions was
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calculated between baseline (S0), week 6 (S1) and week 12 (S2) scans:

∗ 100%.

We also explored the correlation of percent change in FDHT uptake between the single-hottest
lesions at baseline and follow up to BOR (PERCIST-like criteria) (14).
Descriptive statistics summarized baseline and percent change in FDHT uptake. The MannWhitney U test compared baseline and percent change in FDHT uptake between BOR groups.
Pearson correlations were used for continuous data correlating FDHT uptake versus AR status.
At each time point, to account for non-independence among multiple lesions per patient, the
referred as repeated measures correlation (rmcorr) was used to assess the common intra-patient
association for the various paired quantitative PET parameters to each other (15). All P values
are two-sided, and all confidence intervals are at the 95% level, with statistical significance
defined as P

0.05.

RESULTS
Participants and Lesions
Eleven women (median age 59 years, range 47-73) enrolled in the FDHT-PET/CT sub-study
(Table 1) and were scanned between March 2017 and February 2018. Ten were randomized to
receive 9 mg of GTx-024 and one to receive 18 mg. Nine women completed baseline, 6-week,
and 12-week FDHT-PET/CT scans. Two were taken off-study prior to the 12-week scan: one at
week 6 due to toxicity and one at week 7 for PD (Figure 1). BOR was CB for 7 participants and
no CB for 4 participants.
Table 2 shows all participants’ results regarding AR status, FDHT uptake at all time points
and outcomes. FDHT uptake was measured in 40 lesions (median 4 per participant, range 1-8).
Although all lesions were >1 cm in one dimension, a 2D region of interest was used for
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SUV/SUL)max and mean for 13 tumors because either a 1 cm3 sphere could not be placed within
the tumor’s anatomic boundaries or due to low uptake, SUV(/SUL)peak was technically unable
to be determined. At all imaging time points, high correlations were observed between all PET
parameters measured (Supplemental Figure 1). Therefore, the primary analyses are presented
with SUVmax.

AR Status vs. Baseline FDHT Uptake
AR status was assessed in 9 of 11 women; 2 from primary tumor and 7 from metastases.
Seven tumors were AR+ and 2 were AR- (both from metastatic disease). Two women had
inadequate archival tissue available to determine AR status. Median baseline FDHT-SUVmax
was 4.1 (range 1.4-5.9) for AR+ tumor and 2.3 (range 1.5-3.2) for AR- tumor (p=0.22, Figure
2A-C). A weak, not significant, correlation was found for baseline FDHT-SUVmax versus
quantitative AR expression levels (Pearson rho=0.39, p=0.30, Figure 3). SUVmean had similar
results (Supplemental Figure 2).

Baseline FDHT Uptake and Change in FDHT Uptake versus Best Overall Response
Baseline FDHT-SUVmax of the hottest lesion per participant was similar for the 7
participants with CB at 12 weeks after therapy (median 4.1, range 1.4-5.9) compared to the 4
with PD (3.3, 1.5-5.1, p=0.53, Figure 4A). Results were similar for hottest lesion SUVmean and
summed SUVmax and summed SUVmean of all lesions (Supplemental Figure 3).
Participants with CB at 12 weeks tended to have larger declines in FDHT uptake at 6 weeks
(median decline 26.8%, range -42.9 to -14.1%) after starting GTx-024 compared to those with
PD (median decline 3.7%, range -31% to +29%, p=0.11). A similar trend was observed at the 12-
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week FDHT-PET/CT scan with a median decline of 35.7% (range -69.5 to -7.7%) for those with
CB compared to a median decline of 20.1% (-26.6% to +56.5%, p=0.17) for those with PD
(Figures 4B-C, 5). Similar trends were observed for hottest lesion FDHT-SUVmean at 6 and 12
weeks after starting GTx-024 and for summed SUVmax at 6 weeks (Supplemental Figures 4, 5).
6-week summed FDHT-SUVmean declines were larger for those with versus without CB
(p=0.04, Supplemental Figure 6). Percent decrease in FDHT-SUVmax between the single hottest
lesions at baseline and follow up (i.e., PERCIST-like criteria) was significantly larger for those
with CB (percent decline 21.4%, range -42.9% to -14.1%) versus without CB (percent increase
7.6%, range -17.1% to +29.9%, p=0.01) at week 6, but not at week 12 (p>0.5, Supplemental
Figure 7).
Five of seven participants with CB at week 12 after starting GTx-024 progressed by week 24.
The two participants with continued CB at 24 weeks had the largest declines in FDHT uptake at
week 6 and were among the top 3 for largest decline in FDHT uptake at week 12.

FDHT Uptake vs. Hormone and PSA Levels
No correlations were found between baseline FDHT uptake, estradiol, and testosterone levels
(Supplemental Figure 8). There tended to be higher baseline FDHT uptake with lower baseline
SHBG (Supplemental Figure 9). No correlations were found at baseline or during treatment
comparing SUVmax/SHBG to AR status and CB (Supplemental Figure 10). There were no
correlations between baseline FDHT-SUVmax and PSA levels. Although the participant with the
largest decline in FDHT-SUVmax also had categorical declines in PSA levels at 6 and 12 weeks
after starting GTx-024 and CB, no correlations between changes in PSA, FDHT-SUVmax, or
BOR were observed (Supplemental Figure 11).
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DISCUSSION
Despite targeted therapy shifting therapeutic paradigms in many cancers, tumor
heterogeneity, inability to biopsy every lesion, and target conversion within tumor remain
challenges to predict who will benefit from specific therapeutic agents. Non-invasive, wholebody molecular imaging evaluates the entire tumor burden providing one potential solution but
remains a globally underutilized tool for optimizing therapeutic strategies in large clinical trials
(16,17). Our data supplements prior work by demonstrating the feasibility of using FDHTPET/CT for evaluating response to SARM therapy in a large therapeutic clinical trial.
In 13 patients with ER+ MBC who underwent FDHT-PET/CT and metastatic tumor biopsy
within 8 weeks, Venema et al. found a correlation between FDHT uptake and AR expression
(r2=0.47, p=0.01) using a semi-quantitative assessment of >10% nuclear staining as positive for
AR (18). Although not statistically significant, all but one AR+ tumor in our dataset had a
baseline FDHT-SUVmax higher than the findings in AR- tumors suggesting a trend for higher
baseline FDHT uptake in AR+ tumors. One AR- tumor had baseline FDHT uptake greater than
the optimal SUVmax cutoff of 1.9 suggested for differentiating AR+ vs. AR- tumor by FDHTPET/CT (18). Small sample size, tumor heterogeneity, and non-paired lesions for AR status and
FDHT uptake may drive the lack of significance in our dataset. Our results as well as those of
Venema et al. support further investigation of FDHT-PET/CT as an imaging biomarker of AR
expression (18).
AR expression is heterogeneous between primary breast cancer and metastases with
discordance rates up to 33% (19), and in metastases over the natural disease history (20).
Venema et al. reported AR+ primary tumor with AR- metastatic disease in 2 of 13 patients and
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and substantial intra-patient FDHT heterogeneity (18), with patients having both FDHT positive
and negative lesions and FDHT-SUVs ranging from 0.8-6.5.
The therapeutic trial inclusion criteria mandated objective evidence of progression within 30
days of randomization, but standard imaging modalities, i.e., CT and bone scan, for this purpose
often fail to differentiate active disease versus disease that previously responded to treatment.
This likely contributed to tumor heterogeneity in our imaging sub-study. FDG-PET/CT may be
useful to supplement or replace standard imaging to better identify metabolically active tumor
burden and guide interpretation of FDHT-PET/CT. Such a strategy was employed with FESPET/CT imaging for breast cancer bone metastases (21).
Testosterone, DHT, and FDHT competitively bind AR (7), and SHBG binds sex hormones,
including DHT. Categorically low sex hormones levels in this postmenopausal population likely
limited our ability to identify any correlations between baseline FDHT uptake, testosterone,
estrogen or PSA levels. Further, the trend we observed for an inverse relationship between
FDHT uptake and serum SHBG may be explained by SHBG binding decreasing FDHT
availability for tumor binding given the low levels of estrogen and testosterone in our
participants. Kramer et al. used a simplified method to correct SUVbody weight for serum SHBG and
found an improved correlation with Patlak Ki derived from dynamic images (22). We did not
find any statistically significant correlations at baseline or during treatment between
SUVmax/SHBG and AR expression or BOR. Future studies of androgen modulation should be
designed considering hormonal status of the study population.
To our knowledge, this is the first study assessing changes in FDHT uptake on PET in
patients with MBC treated with SARM therapy. Although CB was not associated with baseline
FDHT uptake, those with CB within the first 12 weeks of treatment tended to have larger percent
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declines in FDHT uptake after 6 and 12 weeks of SARM therapy for most of the semiquantitative parameters we explored. All but 2 participants progressed by 24 weeks after starting
therapy, but 2 of the 3 participants with the largest FDHT declines at 6 and 12 weeks after
starting GTx-024 continued to have CB at 24 weeks. Larger studies are needed to determine the
percent decline in SUV that correlates with a clinical disease response.
Boers et al. recently evaluated FDHT-PET/CT for assessing changes in AR availability in 21
patients with AR+ MBC receiving bicalutamide, a pure AR antagonist (23). Like our findings
with GTx-024, baseline FDHT uptake did not predict clinical benefit to bicalutamide. Decreases
in FDHT uptake after 4-6 weeks of bicalutamide also did not predict clinical benefit in the total
study population which included both ER+ and ER- tumors, contrasting our findings. In a
subgroup analysis of 13 patients with ER+ tumor, the authors reported a trend for larger FDHT
uptake declines in 5 patients with clinical benefit from bicalutamide versus 8 with PD (n=8) (23).
Our study only included participants with ER+ breast cancer and our results support the subgroup analysis trend. The different pharmacology between GTx-024 and bicalutamide is also
noted and is important to understand when evaluating imaging biomarkers in specific breast
cancer sub-types.
Early imaging time points would be most advantageous for limiting use of ineffective therapy
and unnecessary toxicities. The PERCIST-like criteria at 6 weeks after starting therapy best
separated those with and without clinical benefit in our cohort. The optimal parameter still needs
to be determined in larger studies.
This study had several limitations, notably the small number of participants enrolled.
Prospectively including an imaging study in a larger therapeutic trial, however, ensured
standardization of FDHT-PET/CT imaging and response assessments using RECIST 1.1. Lesions
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were not paired for AR status and FDHT uptake assessment because the parent therapeutic trial
allowed archival tissue specimens. Although metastases represented most archival tissue
specimens (n=7), they still may not have been from the same site or organ. Additional limitations
are the use of different PET/CT scanners and randomization of one participant to the higher
GTx-024 dose level. Finally, not including FDG-PET/CT, in addition to, or instead of standard
imaging (i.e., CT and bone scan), to identify metabolically active tumor burden to follow for
disease response on a new therapeutic trial remains a challenge. We believe that the inclusion of
noninvasive whole-body functional imaging combining a metabolic tracer such as FDG, and a
specific hormonal targeting agent such as FDHT should be encouraged in this patient population
since it could improve tumor characterization, assess tumor heterogeneity, guide biopsy, help
with decision making and evaluation of therapeutic response, while also helping validate the
investigational specific radiotracer.

CONCLUSION
Our data suggest that FDHT-PET/CT may be a useful imaging biomarker for evaluating
response of MBC to SARM therapy and other AR-expressing malignancies and reiterates the
feasibility of including molecular imaging in multidisciplinary therapeutic trials. Establishing
repeatability and reproducibility of quantitating FDHT uptake in breast cancer and thresholds for
predicting response are required next steps to establish FDHT-PET/CT as a non-invasive
molecular imaging biomarker. This may be challenging given the underlying tumor
heterogeneity seen in hormonally-driven breast cancer.
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KEY POINTS

QUESTION: Does FDHT uptake on PET/CT in metastatic breast cancer correlate with tumor
androgen receptor (AR) status and predict response to selective androgen modulation (SARM)
therapy?
PERTINENT FINDINGS: In a prospective imaging sub-study of 11 women with metastatic
breast cancer receiving SARM therapy, we showed trends associating larger declines in FDHT
uptake after starting therapy with clinical benefit.
IMPLICATIONS FOR PATIENT CARE: With further validation in well-designed clinical
trials, FDHT-PET/CT could be a valuable tool to characterize tumors and direct strategies
modulating AR signaling in breast cancer and other AR positive malignancies.
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FIGURE 1. Study Schema.
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FIGURE 2. Baseline FDHT Uptake and Qualitative Androgen Receptor Status. A) For 9
participants with archival tissue, median baseline FDHT SUVmax was 4.1 (range 1.4 – 5.9) for 7
participants with AR+ tumor and 2.3 (range 1.5 – 3.2) for 2 with AR- tumor (p=0.22). Individual
dots on the boxplot represent individual participant’s data. B) Participant 6 with AR+ tumor and
FDHT uptake in a right femur metastasis (arrows, SUVmax 4.9). C) Participant 8 with ARtumor and no FDHT uptake in a prevascular lymph node (arrows, SUVmax 1.5).
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FIGURE 3. Baseline FDHT Uptake and Quantitative Androgen Receptor Status. A weak,
but not statistically significant, correlation was observed between quantitative AR expression
levels and baseline FDHT uptake (Pearson rho=0.39, p=0.30). (Blue dots: AR+ tumors; red dots:
AR-tumors).
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FIGURE 4. Clinical Benefit at 12 Weeks after Starting Therapy vs. Baseline and Change
in FDHT Uptake. A) For 7 participants with clinical benefit, median baseline FDHT SUVmax
was 4.1 (1.4-5.9) compared to 3.3 (1.5-5.1) for 4 participants with disease progression, p=0.53.
Individual dots on the scatterplot represent individual participant’s data.
Participants with clinical benefit at 12 weeks tended to have larger declines in FDHT uptake
B) at 6 weeks (median decline 26.8%, range -42.9 to -14.1%) after starting GTx-024 compared
to those with disease progression (median decline 3.7%, range -31% to +29%, p=0.11) and C) at
12 weeks (median decline 35.7%, range -69.5 to -7.7%) after starting GTx-024 compared to
those with disease progression (median decline 20.1%, range -26.6% to +56.5%, p=0.17).
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FIGURE 5. A) FDHT-avid AR+ tumor at baseline (top row, arrow SUVmax 4.9) and decline in
FDHT uptake 6 weeks after starting GTx-024 (bottom row, arrow). Best overall response was
stable disease 12 weeks after starting therapy. B) FDHT-avid AR+ tumor at baseline (top row,
arrow SUVmax 5.1), no decline in FDHT uptake and increased tumor size 6 weeks after starting
GTx-024 (bottom row, arrows). Best overall response was progressive disease 12 weeks after
starting therapy.
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TABLES

Table 1. Participant and Breast Cancer Tumor Characteristics (N=11)
Age (median, range)
59 years (49-73 years)
Histology
N
Invasive ductal carcinoma
9
Invasive lobular carcinoma
2
Receptor status
ER+/PR+/HER26
+
ER /PR /HER25
Metastases at Diagnosis
Yes
4
No
7
Metastases at
No Metastases at
Treatment prior to enrollment (median no. lines, range)
Diagnosis (n=4)
Diagnosis (n=7)
Disease-free interval*
not applicable
7 years (3-19 years)
Adjuvant chemotherapy
not applicable
1 (0-1)
Adjuvant endocrine therapy
not applicable
1 (0-2)
Chemotherapy for metastatic disease
1 (0-1)**
0 (0-1)
Endocrine therapy for metastatic disease
2 (1-4)
2 (1-6)
CDK4/6 inhibitor
2
6
mTOR inhibitor
1
2
Dual PI3Kinase mTOR inhibitor
0
1
Radiation therapy to metastatic disease
1 (bone)
2 (bone)
Median number of metastatic sites at enrollment (range)
2 (1-4)
Location of metastatic sites at enrollment
Bone (bone-only)
8 (5)
Visceral (liver, vaginal cuff)
4
Pleura
5
Serosa/peritoneal
2
Lymph node
2
*disease-free interval: time from adjuvant therapy start to first diagnosis of recurrence/metastatic disease
**n=1 with high-dose chemotherapy and stem cell transplant
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Participant

No. of
Lesions

1*

3

2

2

3

2

4

1

5

8

6

4

7

5

8

1

9

5

10

4

11

5

Table 2. Androgen Receptor (AR) Tumor Status, FDHT-PET/CT, and Clinical Outcomes
% Change FDHT-SUVmax
Outcomes
Baseline to
Baseline
FDHT-SUVmax
Time of Best Overall Response
AR Status/Archival Tissue Location
Hottest Lesion
Week 6
Week 12
Best Overall Response
Week:
positive/primary
§
4.1
-43%
-70%
nonCR/nonPD
12
positive/metastasis
3.5
-37%
-36%
nonCR/nonPD§
12
positive/metastasis
1.4
-20%
-8%
nonCR/nonPD§
12
not assessed
†
3.3
-20%
Off-study
nonCR/nonPD§
6
positive/metastasis
4.8
-14%
-22%
PR
12
positive/metastasis
4.9
-36%
-35%
SD
12
positive/primary
5.9
-27%
-48%
SD
12
negative/metastasis
1.5
+30%
+56%
PD
12
not assessed
5.1
+10%
-20%
PD
12
negative/metastasis
†
3.2
-17%
Off-study
PD
7
positive/metastasis
3.4
-31%
-27%
PD
12
*Received 18 mg GTx-024; all others received 9 mg GTx-024
†
Baseline and week 6 scan only; #4 off study week 6 due to toxicity, #10 off study week 7 due to progression
§
nonCR/nonPD denotes incomplete response but no disease progression for participants with non-measurable disease by RECIST 1.1
Response by RECIST 1.1: CR- complete response; PR: partial response ; SD: stable disease ; PD: progressive disease

Week 24 Response
Clinical benefit
Clinical benefit
No clinical benefit
No clinical benefit
No clinical benefit
No clinical benefit
No clinical benefit
No clinical benefit
No clinical benefit
No clinical benefit
No clinical benefit

SUPPLEMENTAL DATA
Supplemental Figure 1. Correlations of Semiquantitative Parameters of FDHT Uptake. SUVmax, SUVpeak and SUVmean were
highly correlated.

Supplemental Figure 2. Correlation of Baseline FDHT SUVmean and Qualitative and Quantitative AR Status.

A) For 9 participants with archival tissue assessed for AR status, median baseline FDHT SUVmean was 3.4 (1.4-4.8) for 7 participants
with AR positive tumor and 2.0 (1.4-2.7) for 2 with AR negative tumor (p=0.22). The individual dots on the scatterplot represent
individual participant’s data. B) There was a weak correlation between quantitative AR expression levels and baseline FDHT uptake,
but this was not statistically significant (Pearson rho=0.42, p=0.26). Blue dots represent participants with AR positive tumor. Red dots
represent participants with AR negative tumor.

Supplemental Figure 3. Clinical Benefit at 12 Weeks after Starting Therapy vs. Baseline FDHT SUVmean, summed SUVmax,
and summed SUVmean.

There were no significant differences between A) baseline FDHT SUVmean, B) baseline FDHT summed SUVmax, or C) baseline
FDHT summed SUVmean and clinical benefit at 12 weeks after starting treatment with GTx-024. The individual dots on the
scatterplot represent the individual participant’s data.

Supplemental Figure 4. Clinical Benefit at 12 Weeks after Starting Therapy vs. Change in FDHT Uptake: SUVmean

Participants with clinical benefit at 12 weeks tended to have larger declines in FDHT uptake for SUVmean (hottest lesion) at (A) 6
weeks after starting GTx-024 and (B) 12 weeks after starting GTx-024.

Supplemental Figure 5. Clinical Benefit at 12 Weeks after Starting Therapy vs. Change in FDHT Uptake: summed FDHT
SUVmax

Participants with clinical benefit at 12 weeks tended to have larger declines in FDHT uptake for summed SUVmax at (A) 6 weeks
after starting GTx-024, but not at (B) 12 weeks after starting GTx-024.

Supplemental Figure 6. Clinical Benefit at 12 Weeks after Starting Therapy vs. Change in FDHT Uptake: summed FDHT
SUVmean

Participants with clinical benefit at 12 weeks tended to have larger declines in FDHT uptake for summed SUVmean at (A) 6 weeks
after starting GTx-024, but not at (B) 12 weeks after starting GTx-024.

Supplemental Figure 7. Clinical Benefit at 12 Weeks after Starting Therapy vs. Change in FDHT Uptake Using PERCISTlike Criteria.

A) Participants with clinical benefit at 12 weeks had larger declines in FDHT SUVmax comparing the hottest lesion at baseline to the
hottest lesion at week 6 (median decline 21.4%, range -42.9 to -14.1%) after starting GTx-024 compared to those with disease
progression (6 weeks: increase 7.6%, range -17.1%to +29.9%, p=0.012). B) No significant differences were seen comparing the
change in FDHT SUVmax of the hottest lesion at baseline to the hottest lesion at week 12 after starting GTx-024 between those with
and without clinical benefit (p>0.5).

Supplemental Figure 8. Baseline FDHT uptake in tumor vs. baseline estradiol and testosterone levels. No correlations were
observed.

Supplemental Figure 9. Baseline FDHT uptake in tumor vs. baseline sex-hormone binding globulin levels. A trend towards
higher baseline FDHT uptake with lower baseline sex-hormone binding globulin levels was observed.

Supplemental Figure 10. FDHT SUVmax/SHBG versus AR Status at Baseline and Clinical Benefit at 12 weeks: No correlations
were observed.

Supplemental Figure 11. Change in PSA levels, FDHT uptake and best overall response.

No correlations were observed. At baseline, 10 participants had PSA levels assessed. At 6 weeks after starting GTx-024, 2 participants
did not have PSA assessable for change: 1 with clinical benefit and 1 without clinical benefit. At 12 weeks after starting GTx-024, 5
participants did not have PSA assessable for change: 2 with clinical benefit and 3 without clinical benefit.

